Compare ARI & CTMX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ARI | CTMX |
|---|---|---|
| Founded | 2009 | 2008 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 884.4M | 716.9M |
| IPO Year | 2009 | 2015 |
| Metric | ARI | CTMX |
|---|---|---|
| Price | $6.54 | $2.76 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 3 | 10 |
| Target Price | $11.00 | ★ $12.10 |
| AVG Volume (30 Days) | 2.2M | ★ 3.5M |
| Earning Date | 04-28-2026 | 05-08-2026 |
| Dividend Yield | ★ 9.31% | N/A |
| EPS Growth | ★ 183.51 | N/A |
| EPS | ★ 0.27 | N/A |
| Revenue | ★ $271,589,000.00 | $76,201,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $7.61 |
| P/E Ratio | $24.11 | ★ $22.58 |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $6.43 | $1.90 |
| 52 Week High | $11.24 | $8.21 |
| Indicator | ARI | CTMX |
|---|---|---|
| Relative Strength Index (RSI) | 27.48 | 29.17 |
| Support Level | $6.43 | N/A |
| Resistance Level | $7.00 | $3.93 |
| Average True Range (ATR) | 0.10 | 0.22 |
| MACD | 0.02 | -0.07 |
| Stochastic Oscillator | 2.33 | 2.05 |
Apollo Commercial Real Estate Finance Inc is a real estate investment trust that originates, invests in, acquires, and manages commercial first-mortgage loans, subordinate financings, commercial mortgage-backed securities, and other real estate-related debt investments. The subordinate loans and first-mortgage loans account for the vast majority of the portfolio on a cost basis. Property types include residential, retail, healthcare, office, mixed-use, hotel, industrial, multifamily, securities, and other, with residential properties and hotels representing the highest property value. More than a third of the properties are located in New York City, with the other properties located across other regions of the United States, as well as other countries.
CytomX Therapeutics Inc a clinical-stage, oncology-focused biopharmaceutical company developing novel, masked, conditionally activated biologics designed to be localized to the tumor microenvironment. It is engaged in developing antibody therapeutics based on probody technology platforms. The company's probody technology platform creates proprietary cancer immunotherapies against clinically-validated targets and develops cancer therapeutics. Probody therapeutics are designed to take advantage of conditions in the tumor microenvironment to enhance the tumor-targeting features of an antibody and reduce drug activity in healthy tissues.